Protalix Biotherapeutics, Inc. Announces First Patient Treated in Phase I/II Study of Fabry Patients With PRX-102
Published: Dec 10, 2012
CARMIEL, Israel, Dec. 10, 2012 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), announced today that the first patient has been treated in the Company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the Company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy (ERT) for the treatment of Fabry disease.